Document Detail

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.
MedLine Citation:
PMID:  23387937     Owner:  NLM     Status:  Publisher    
ABSTRACT Progression or relapse occurs in the vast majority of patients with multiple myeloma (MM) who undergo up-front autologous haematopoietic cell transplantation (AHCT1), which remains a cornerstone of treatment in the era of novel agents. Limited data are available regarding the value of salvage therapy with a second AHCT (AHCT2) in patients who relapse/progress after AHCT1. We analysed the outcome of 83 patients who underwent salvage AHCT2 between 1994 and 2011. Most patients (77%) had received treatment with novel agents between AHCT1 and AHCT2, and 28% of patients were from ethnic minority groups. Median overall survival (OS) from AHCT2 was 31.5 months (95%CI: 22 - 41), and median progression-free survival (PFS) was 15.5 months (95%CI: 11-20). In multivariate analysis, only disease status (≥PR) at AHCT2 was associated with better OS. The 3-year OS rates for patients receiving AHCT2 in >PR and PR were 85.9% (95%CI: 61-96) and 51.3% (95%CI: 34-68), respectively. Disease status at AHCT2 and time to progression/relapse after AHCT1 were associated with PFS in multivariate analysis. In summary, salvage AHCT2 is an effective treatment option in patients with chemosensitive relapse/progression and prolonged remission after a prior autograft.
Holger W Auner; Richard Szydlo; Alero Rone; Aristeidis Chaidos; Chrissy Giles; Ed Kanfer; Donald H Macdonald; David Marin; Dragana Milojkovic; Jiri Pavlu; Jane F Apperley; Amin Rahemtulla
Related Documents :
23900217 - Notch-induced transcription factors are predictive of survival and 5-fluorouracil respo...
25076247 - Relationship of mda plasma concentrations to long-term survival of breast cancer patients.
22020577 - Prognosis and risk factors for early-stage adenoid cystic carcinoma of the major saliva...
23016517 - Phase i study of concurrent weekly docetaxel, high-dose intensity-modulated radiation t...
17409967 - Phase ii study of carboplatin, irinotecan, and thalidomide in patients with advanced no...
21553277 - Tm:yag laser en bloc mucosectomy for accurate staging of primary bladder cancer: early ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-2-7
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  -     ISSN:  1029-2403     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-2-7     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  PAA-PAMPS Copolymers as an Efficient Tool to Control CaCO3 Scale Formation.
Next Document:  Impedance-based outflow boundary conditions for human carotid haemodynamics.